GET DAILY SIGNALSOmniAb (OABI) Reports +81.4% Revenue Growth in Q3 2026 and Raises Full-Year Guidance
Key Takeaways
- OmniAb reported third quarter 2026 revenue of roughly $4.0 million, an 81.4% year-over-year increase from $2.2 million, exceeding consensus estimates.
- GAAP net loss per share came in at approximately $0.12, essentially in line with analyst expectations.
- Management raised its full-year 2026 revenue guidance to a range of $35 million to $39 million, up from the prior $32 million to $36 million outlook.
- Nine-month revenue reached $31.8 million, compared with $10.3 million in the prior-year period, driven primarily by milestone revenue.
- Growth was fueled by higher service revenue, expansion of the xPloration platform, and strong instrument sales across antibody and ion channel programs.
- The company ended the quarter with 34 active clinical programs and approved products, plus more than $3 billion in total contracted potential milestones.
Earnings Context and Why It Matters
OmniAb, Inc. (OABI) licenses discovery research technology to pharmaceutical and biotech companies to support the development of next-generation therapeutics. Because the company's revenue is heavily milestone-driven, quarterly results can be uneven, making each report an important checkpoint on partner-program progression rather than a simple measure of recurring sales. The third quarter 2026 print carries particular weight because it follows a sharp, front-end-loaded surge in milestone revenue earlier in the year. I was watching whether service momentum and the commercial rollout of the xPloration platform could sustain growth after a period of milestone-driven variability, and whether management would adjust its full-year outlook in response to the stronger top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, OmniAb reported revenue of approximately $4.0 million, up from $2.2 million in the same period last year, an increase of 81.4%. The result beat consensus estimates of roughly $3.56 million. The top-line growth was driven primarily by higher service revenue and xPloration revenue, supported by work on both antibody and ion channel programs and by strong instrument sales.
On the bottom line, the company posted a GAAP net loss of about $0.12 per share, essentially matching consensus expectations. Total costs and operating expenses were approximately $20.4 million, unchanged from the prior-year period, as lower research and development (R&D) spending was partially offset by higher general and administrative (G&A) costs and increased cost of sales tied to instrument placements.
For the nine-month period, revenue totaled $31.8 million, versus $10.3 million a year earlier, reflecting the milestone-heavy nature of 2026 results. Management also raised its full-year revenue guidance to between $35 million and $39 million, up from the previous $32 million to $36 million range, signaling continued confidence in the company's commercial momentum. From what I see, this upward revision highlights the underlying strength in the business.
Market Reaction and Investor Sentiment
Sentiment around OABI heading into the report was shaped by the company's earlier 2026 momentum, including a second-quarter earnings beat and a licensing agreement with Eli Lilly for an ion channel program worth up to $370 million. The third-quarter revenue beat and upward guidance revision reinforced that narrative, with management emphasizing progress across its partner pipeline, expanding technology offerings, and the commercial rollout of the xPloration platform. Investors have continued to weigh the company's recurring-revenue potential against its ongoing net losses, with attention focused on whether service and instrument-led growth can reduce the historical reliance on lumpy milestone payments.
Forward Outlook and Key Factors to Monitor
Following the third-quarter report, investors will likely focus on whether OmniAb can convert its expanding installed base into durable, recurring revenue. Management expects xPloration revenue of $2 million to $3 million in 2026, with that figure projected to double in 2027 and again in 2028 as consumables, software licenses, and service contracts scale.
Milestone and royalty activity remains a central driver. The company reported more than $3 billion in total contracted potential milestones, with an average royalty rate of approximately 3.4%, and roughly $340 million in remaining potential milestones tied to its active clinical programs. The number of clinical entrants and downstream regulatory events among partners will therefore be key swing factors for future quarters. I’m watching this closely as those events unfold.
Finally, investors should watch cost discipline, the pace of new partnership signings, and the adoption of newer discovery technologies. Service revenue from the Eli Lilly collaboration is expected to begin contributing in the fourth quarter, offering an early read on how these agreements translate into near-term results. As always, milestone timing will keep quarterly results variable.
Using Tickeron’s AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener have become a regular part of how I evaluate companies such as OABI. The platform lets me quickly filter for relevant technical patterns, fundamentals, and industry trends, which helps put quarterly results into broader context without spending hours on manual research. It is especially useful when tracking milestone-driven names where timing can shift quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OABI in -3.22% downward trend, sliding for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OABI declined for three days, in 209 of 251 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
OABI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OABI as a result. In 58 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for OABI just turned positive on October 28, 2026. Looking at past instances where OABI's MACD turned positive, the stock continued to rise in 26 of 48 cases over the following month. The odds of a continued upward trend are 54%.
Following a +14.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where OABI advanced for three days, in 151 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 94 of 187 cases where OABI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.854) is normal, around the industry mean (3.154). P/E Ratio (-14.194) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (14.124) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OABI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OABI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement